SK Plasma Expands Cancer Portfolio With Velcade Distribution

SK plasma is a Korean company specialising in plasma-derived products, the firm revealed that it has signed an exclusive distribution agreement with Janssen Korea, the pharmaceutical arm of Johnson & Johnson. The deal grants SK plasma exclusive rights to distribute and market Velcade (bortezomib triple complex) in South Korea. 

Velcade is a treatment for multiple myeloma and mantle cell lymphoma. Under this partnership, Janssen Korea will continue to manufacture and supply the drug, while SK plasma will handle its domestic distribution and marketing. This deal strengthens SK plasma’s portfolio of blood cancer treatments by adding Velcade for multiple myeloma and malignant lymphoma to its lineup. The company’s current offerings include Dacogen (decitabine), a treatment for myelodysplastic syndrome and acute myeloid leukemia.

Kim Seung-Joo, CEO of SK plasma, said, “This agreement not only strengthens our oncology portfolio but also enables us to provide a widely recognized standard therapy for multiple myeloma patients,”

In 2023, SK plasma acquired the exclusive domestic marketing rights for Janssen Korea’s Dacogen. Dacogen is an anti-neoplastic drug used in the treatment of myelodysplastic syndrome and acute myeloid leukaemia. Since then, the company has been actively promoting the drug as part of its expanding focus on cancer treatments.